Invega Trinza 350 mg

Invega Trinza 350 mg is an extended-release suspension of palperidone palmitate for intramuscular use. It is designed for long-term management of certain mental health conditions. This medication is administered by healthcare professionals to provide sustained symptom control.

Invega Trinza 350 mg is primarily used for the maintenance treatment of schizophrenia in adults who have been stabilized on palperidone palmitate. This extended-release suspension is designed to provide long-lasting effects, reducing the frequency of injections compared to other formulations. It is often used for individuals who require consistent management of their symptoms over an extended period.

Common effects of Invega Trinza 350 mg may include injection site reactions, weight gain, and changes in metabolism. Some individuals may experience drowsiness, dizziness, or restlessness. It is important to discuss any persistent or severe side effects with a healthcare provider.

Invega Trinza 350 mg should be administered by a healthcare professional experienced in the use of long-acting injectable antipsychotics. Regular monitoring is recommended to assess for potential side effects and to ensure the medication is working as intended. It is important to inform your healthcare provider about any other medications you are taking to avoid potential interactions.

Invega Trinza 350 mg may interact with other medications, including those that affect the central nervous system, such as sedatives or antidepressants. Alcohol and certain over-the-counter medications may also interact with this suspension. Always consult a healthcare provider before starting or stopping any medication.